ESTRO 2025 - Abstract Book

S3803

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2025

Conclusion: CoxPH estimates supported our hypothesis that larger tumor nuclear size resulted in decreased cell survival and improved clinical outcomes following radiotherapy treatment of gynecological SCC, warranting further large-scale pan-cancer studies. Increased variability in nucleus size distribution, particularly with a higher presence of smaller nuclei, may lead to underdosing of tumor nuclei due to their size, resulting in poorer clinical outcomes. This highlights the importance of multiscale dosimetry and the need to account for patient-specific variations in nuclear size when prescribing personalized radiation doses to optimize treatment outcomes in clinical practice. References: 1. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nature genetics. 2013;45(10):1113-20. 2. Hou L, Gupta R, Van Arnam JS, Zhang Y, Sivalenka K, Samaras D, et al. Dataset of segmented nuclei in hematoxylin and eosin stained histopathology images of ten cancer types. Scientific data. 2020;7(1):185. 3. Pocock J, Graham S, Vu QD, Jahanifar M, Deshpande S, Hadjigeorghiou G, et al. TIAToolbox as an end-to-end library for advanced tissue image analytics. Communications medicine. 2022;2(1):120. 4. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. International Journal of Gynecology & Obstetrics. 2021;155:28-44. Keywords: tumor biomarker, personalized multiscale dosimetry